论文部分内容阅读
1 病例与方法 7例病人均为本院1987年12月至1992年12月经维甲酸(RA)为主治疗取得完全缓解(CR)的急性白血病患者,其中急性早幼粒细胞白血病(M_3)6例,M_21例。中位年龄21岁(12～58岁)。男4例,女3例。均为初治病例。一般RA60～80mg/d,分2～3次口服,平均用量1550 mg,疗程3-4周。 7例患者达CR后均停用RA。3例因经济困难等原因未作维持及强化治疗;4例接受规则的H-A交替序贯维持治疗和间断MDA强化治疗,即CR后第1年每月单用高三尖杉酯碱(H)(1mg/d,肌注,10d为一疗程)或阿糖胞苷(A)(50mg/d,肌注,10d为一疗程)交替维持,每3个月给一次中剂量阿糖胞
1 Cases and Methods All 7 patients were acute leukemia patients who had complete remission (CR) treated with retinoic acid (RA) from December 1987 to December 1992. The patients with acute promyelocytic leukemia (M_3) 6 Cases, M_21 cases. The median age of 21 years (12 to 58 years old). 4 males and 3 females. Are initial treatment cases. General RA60 ~ 80mg / d, 2 to 3 times orally, with an average dose of 1550 mg, course of 3-4 weeks. All 7 patients discontinued RA after reaching CR. 3 cases were not maintained and intensive treatment because of financial difficulties and other reasons; 4 cases of regular alternating HA HA and intermittent maintenance therapy, that is, the first year after CR alone with homoharringtonine (H) 1mg / d, intramuscular injection, 10d for a course of treatment) or cytarabine (A) (50mg / d, intramuscular injection, 10d for a course of treatment) were alternately maintained every 3 months to give a dose of cytarabine